Introduction
Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CNS) characterized by an autoimmune inflammatory reaction to myelin components leading to oligodendrocyte death, demyelination and axonal damage [1] . The clinical disease course usually starts with reversible episodes of neurological disability (relapsing-remitting MS, or RRMS), and later develops into a progressive stage with irreversible neurological decline (secondary progressive MS, or SPMS). Axonal loss is considered the main contributor to clinical disability [2] and occurs in both the acute and chronic phases of MS and its animal model, experimental autoimmune encephalomyelitis (EAE). Likewise, activated microglia and macrophages are thought to contribute to neurodegeneration, as their number correlates with the extent of axonal damage in MS lesions [3, 4] . One mechanism that could link activated microglia and macrophages to the formation of multiple sclerosis lesions could be the release of glutamate through the cystine/glutamate antiporter [5, 6] . Indeed, glutamate-mediated excitotoxicity is an important process in MS pathogenesis promoting oligodendroglial cell death and demyelization [7, 8] . Neuroimaging techniques such as positron emission tomography (PET) have provided valuable information about the inflammatory component in MS, monitoring changes in regional glucose metabolism and the presence of activated microglia/ macrophages in sclerotic plaques [9, 10] . PET imaging of glucose metabolism with [ 18 F]FDG has been applied to quantify inflammation due to the high metabolic rate of activated immune cells in EAE, the rat model for MS [11, 12] and in patients with MS [9] . Besides, radioligands that target the mitochondrial 18KDa translocator protein (TSPO) have been used for imaging microglia/ monocytes in patients and animal models of MS [10, [13] [14] [15] [16] [17] . [ 11 C]PK11195, the first TSPO radiotracer to be successfully applied in MS patients, has been able to detect the infiltration of monocytes in acute demyelinated lesions [18, 19] . Despite these advances, we still need new PET imaging techniques that correlate MS pathology with clinical disability in order to study disease progression and monitor the response to therapeutic drugs. In this regard, the evaluation of cystine/glutamate antiporter (system xc − ) following MS has been scarcely explored to date and might be a potential candidate for PET imaging of M S . ( 4 S ) -4 -( 3 -( 1 8 ) F -f l u o r o p r o p y l ) -l -g l u t a m a t e ([ 18 F]FSPG) is a novel radiotracer to assess xc − transporter activity with PET that has been proposed as a promising radioligand presenting a wide range of diagnostic applications, from cancer to neurologic diseases [20] [21] [22] . Therefore, the purpose of the present study was to investigate xc − transporter activity in rat central nervous system 
Materials and methods

Induction of experimental autoimmune encephalomyelitis and treatment
Adult male Lewis rats (8 weeks old, weighing 200-220 g) (n= 21) were used. Animal studies were approved by the animal ethics committee of CIC biomaGUNE and local authorities, and were conducted in accordance with the Directives of the European Union on animal ethics and welfare. EAE was induced by subcutaneous injection of inoculum containing 100 μg of guinea pig myelin basic protein (Sigma) diluted in water, emulsified in equal volumes of Freund's incomplete adjuvant (Sigma) and supplemented with 500 μg of heatinactivated M. tuberculosis H37Ra (DIFCO Laboratories) in both hind feet. Eleven rats were repeatedly examined before (day 0) and at 7, 14, 21 and 28 after EAE induction to evaluate the temporal PET binding of glucose metabolism (n=6), TSPO (n=6) and xc − (n=5). The animals studied at day 0 have been considered as the baseline control group. Likewise, four of these six rats were also subjected to MRI scans. Eight days after EAE induction, a group of ten rats were deeply anaesthetized with ketamine/xylazine and stereotactically injected in both lateral ventricles (AP −1.0 mm; L±1.5 mm; DV −4.0 mm from skull) with a blunt Hamilton syringe loaded with 15 μL of clodronate-containing liposomes (n=5; 5 mg/mL; ClodLip BV, Netherlands) or PBS-containing liposomes (n=5) at a flow rate of 1 μL/min. Both suspensions were gently mixed by inversion immediately before loading the syringe. No mortality was observed after the clodronate or PBS injection. At day 14, treated and control rats were imaged with PET to determine the effect of clodronate on the system xc − function.
Neurological evaluation
The neurological impairment was monitored and scored daily on every animal from day 10 to day 28 post immunization according to the following scale ranging from 0 to 8: 0, normal; 1, flaccid tail; 2, tail paralysis; 3, loss of muscle tone in hindlimbs; 4, hindlimbs hemiparalysis; 5, complete hindlimbs paralysis; 6, moderate paraparesis; 7, tetraparalysis; 8, death. Total score could range from 0 (normal) to 8 (highest handicap) point-scale.
Magnetic resonance imaging
MRI scans were performed in rats (n=4) before (day 0) and at 7, 14, 21 and 28 days after EAE induction. Before the scans, anesthesia was induced with 4 % isoflurane and maintained by 2-2.5 % of isofluorane in 100 % O 2 during the scan. Animals were placed into a rat holder compatible with MRI acquisition systems and maintained normothermic using a water-based heating blanket at 37°C. Measurements were performed by using an 11.7 T Bruker Biospec system (Bruker, Ettlingen, Germany) with a 72 mm volumetric quadrature coil for excitation and a commercial 20 mm rat brain surface coil for reception. Acquisition parameters were as follows; Gradient echo sequence TR/TE=500/2 ms, fov=30×30 mm, ACQ matrix=256×256, slice thickness =0.50 mm, number of slices =40.
Magnetic resonance imaging image analysis
The MRI images were used to calculate the brain ventricle volume. Regions of interest were manually defined using the Open Source software 3D Slicer image analysis software (Version 3.6.3; www.slicer.org) for each rat on the region of brain ventricles. The total brain ventricle volume was calculated by summing the area of the ventricle region of all slices.
Radiochemistry
The production of [ with N-Methyl-2-(2-amino-4-cyanophenylthio)-benzylamine (MASB, 1 mg in 80 μL of dimethylsulfoxide, ABX, Radeberg, Germany) using the captive solvent method [23] (reaction time = 6 min, T = 25°C). Purification by high performance liquid chromatography (HPLC) and reformulation using solid phase extraction yielded the final solution of pure injectable tracer. The presence of the labeled species was confirmed by HPLC and co-elution with reference standard. Typical radiochemical yields (RCY) and specific activities (SA) were 33±5 % (end of bombardment, EOB) and 135± 18 GBq/μmol (end of synthesis), respectively (total synthesis time=50 min). Radiochemical purity was >98 %.
The synthesis of (4S)- 18 F-fluorination of the protected precursor di-tert-butyl (2S,4S)-2-tertbutoxycarbonylamino-4-(3-nitrophenylsulfonyloxy-propyl)-pentanedioate, followed by acidic hydrolysis. The precursor preparation and the radiolabeling were carried out as previously described [24] . Radiochemical yields (EOB) were in the range 30-35 % and radiochemical purity was always >93 % at the time of injection.
[ Positron emission tomography scans and data acquisition PET scans were performed before (day 0) and at 7, 14, 21 and 28 days after EAE induction using a General Electric eXplore Vista CT camera (GE Healthcare). Scans were performed in rats anaesthetized with 4 % isofluorane and maintained by 2-2.5 % of isofluorane in 100 % O 2 . The tail vein was catheterized with a 24-gauge catheter for intravenous administration of the radiotracer. Animals were placed into a rat holder compatible with PET acquisition system and maintained as normothermic using a water-based heating blanket. (1) A group of six animals was subjected to two PET scans to assess TSPO binding ([ Positron emission tomography image analysis PET images were analyzed using PMOD image analysis software version 3.506 (PMOD Technologies Ltd, Zürich, Switzerland). To verify the anatomical location of the signal, PET images were co-registered to the anatomical data of the CT of the same animal. Five types of Volumes of Interest (VOIs) were established along the central nervous system. Two VOIs were generated in the brain (cerebrum and the cerebellum) and three VOIs in the spinal cord ( c e r v i c a l , t h o r a c i c a l a n d l u m b a r ) t o e v a l u a t e [ 11 C]PK11195, [ 18 F]FDG and [ 18 F]FSPG PET signal over time. VOIs were manually drawn in the inner part of the selected regions using the rat CT image for each PET scan. Therefore, the reduced size of the VOI in the spinal cord with regard to the resolution of the PET scanner may lead to a partial volume effect that could affect the PET binding on this particular region. For static [ 18 F]FDG PET scans quantification, the mean value and the standard deviation (mean±sd) of each VOI corresponding to the total uptake for 60 min were expressed as percentage of injected dose per cubic centimeter (%ID/cc). For dynamic PET studies, last time frames in steady state were used to calculate the summed PET binding uptake during the last 16 and 20 min of acquisition for [
11 C]PK11195 and [ 18 F]FSPG, respectively. Finally, PET signal frames were summed and voxels outside the selected VOIs were masked to better represent the PET binding in the central nervous system using PMOD software.
Immunohistochemistry
To check microglial depletion, 7 days after clodronate injection (15 days after EAE induction), rats were anaesthetized with chloral hydrate (200 mg/ml, 0.5 g/kg) and perfused with 0.1 M phosphate buffer (PB) followed by paraformaldehyde (PFA) 4 % in 0.1 M PB. Free-floating spinal cord vibratome sections (50 μm) were incubated in blocking-permeabilization solution containing 0.1 % Triton-X100 and 5 % NGS in PBS for 1 h at room temperature (RT). Slices were subsequently incubated with the rabbit anti-Iba1 (Wako, 1:200) overnight at 4°C. After three washing steps in PBS, tissue was incubated with goat anti-rabbit Alexa Fluor® 488 (1:200; Molecular Probes) for 1 h at RT in darkness. Slices were stained with Hoechst for nuclear identification and imaged using an Olympus Fluoview FV500 confocal microscope. For quantification of Iba1 staining, Z-stacks (step size=0.5 μm) were obtained in spinal cord (lumbar portion, longitudinal sections) of at least three slices per animal. The area stained was calculated with ImageJ software (NIH, USA) using an automatic default threshold applied on the maximal projection of each stack, to sample all possible planes and avoid bias by antibody penetration.
Statistical analyses
For PET signal values, the statistical analysis was performed as follows; %ID/cc for each animal, brain region (cerebrum and cerebellum) and spinal cord (cervical, thoracic and lumbar) were calculated at each time point. %ID/cc values within each region and time point were averaged and compared with the averaged baseline control values (before EAE induction) using one-way ANOVA followed by Dunnet's multiplecomparison tests for post hoc analysis. The effect of clodronate in EAE rats was compared with control EAE rats using an unpaired t test. The level of significance was regularly set at p<0.05. Statistical analyses were performed with GraphPad Prism version 4.02 software.
Results
In vivo imaging experimental set-up based on clinical outcome of EAE The clinical severity of EAE in Lewis rats was monitored from day 10 to day 28 after immunization. All immunized rats developed typical clinical signs of acute EAE. The first clinical signs occurred over day 10 after EAE induction with both tail paralysis and loss of muscle tone in hindlimbs. Subsequently, disease progressed from hemiparalysis at days 12 to 13 to complete hindlimbs paralysis at day 14 post-immunization. EAE symptoms persisted for about 7 days followed by a progressive recovery from day 21 to day 28 after EAE induction (Fig. 1 Fig. 1) .
Ventricle volume evolution after EAE
We applied MRI-T 1 W imaging to investigate the pathological manifestations after EAE induction. Images showed ventricle volume evolution at control (day 0) and 7, 14, 21 and 28 days after EAE induction (Fig. 2a-e) . Rat ventricle volume increased significantly from circa 13 mm 3 at day 0 to ca. 25 mm 3 at day 14, and as followed by a progressive decrease to reach control values at day 28 after immunization (p<0.05, Fig. 2f ). These results evidenced that the highest brain ventricle volume following EAE run in parallel with the peak of clinical severity of the disease in rats.
PET Imaging of glucose metabolism in EAE-induced rats
Next, we studied the glucose metabolism using [ 18 F]FDG in brain (cerebrum, cerebellum) and spinal cord after EAE induction (Fig. 3, n=6, 1 rat died between days 14-21 ). The images with normalized color scale illustrate the evolution of the PET signals in the central nervous system (CNS) at control (day 0) and days 14 and 28 after EAE induction (Fig. 3a-c) . PET images evidenced a higher [ 18 F]FDG binding uptake in the brain than in the spinal cord at different time points before and after EAE induction (Fig. 3a-c) . In the whole brain, the binding values for [ 18 F]FDG presented a slight decrease at 7 days post immunization, followed by a nonsignificant increase of the PET signal from day 14 to day 28 after EAE induction compared to control (day 0) values ( Fig. 3d-e) . Likewise, the glucose metabolism of the cervical spinal cord over time showed similar values than that observed before immunization (Fig. 3f) . In the thoracic spinal cord, [ 18 F]FDG evidenced a nonsignificant hypometabolism over the following month post immunization (Fig. 3g) . These results stand in agreement with the reduction of the glucose metabolic rate in patients with multiple sclerosis [25, 26] . In contrast, lumbar spinal card showed similar [ (Fig. 3h) . Therefore, these results did not demonstrate the existence of a correlation between the consumption of glucose with the progression of the disease over time.
TSPO imaging with [ 11 C]PK11195 PET after EAE induction
The time course of TSPO was evaluated using [ 11 C]PK11195 in brain (cerebrum, cerebellum) and spinal cord (cervical, thoracic and lumbar) after EAE induction (Fig. 4, n=6 , one rat died between days 14-21). Representative images of whole body scans showed the [ 11 C]PK11195 binding distribution in the CNS at 0, 14 and 28 days after immunization (Fig. 4a-c) . The intact or non-inflamed cerebral tissue shows a very low TSPO receptor expression followed by a dramatic upregulation due to the inflammatory reaction evidencing it usefulness to image neuroinflammatory processes [27] . This fact has been supported by the very low [ 11 C]PK11195 binding level observed at the regions evaluated before (day 0) the EAE induction. Likewise, all studied regions in brain and spinal cord have exhibited a similar TSPO over-expression following EAE (Fig. 4) . The cerebrum was the region of the central nervous system that experienced the lowest [
11 C]PK11195 increase following EAE induction. At day 14, a nonsignificant increase of TSPO expression with respect to control (day 0) was followed by a subsequent decrease from days 21 to 28 post immunization (Fig. 4d) . In contrast, the cerebellum showed a significant increase of the [ 11 C]PK11195 PET signal at day 14 followed by a progressive decrease later on (P<0.05 with respect to control animals, Fig. 4e ). In the spinal cord, [ 11 C]PK11195 displayed a progressive increase from day 0, peaking at day 14 and followed by a progressive signal decline from day 21 to day 28 after EAE induction (p<0.05 with respect to control animals, Fig. 4f-h ). Altogether, these results evidenced a global increase of the inflammatory reaction and TSPO over-expression in the spinal cord and cerebellum that stand in agreement with both the clinical features and the ventricle volume increase of acute EAE in rats.
PET xc
− binding uptake in CNS after EAE Cystine/glutamate antiporter system function was evaluated with [
18 F]FSPG in brain (cerebrum and cerebellum) and spinal cord (cervical, thoracic and lumbar) after EAE induction (Fig. 5, n=5) . Representative images illustrate the evolution of the [ (Fig. 5a-c Fig. 5d  and e) . Spinal cord evidenced a higher xc-expression at control (day 0) conditions in comparison to that in brain ( Fig. 5f-h ). At day 7, both cervical and thoracic spinal cord sections showed a nonsignificant [ Fig. 5f and g ). In contrast, lumbar spinal cord showed a significant over-increase of the [ 18 F]FSPG PET signal at day 14 followed by a progressive decrease from day 21 The upper right panels of each figure show the selected ROIs for the quantification defined in a representation of the rat central nervous system. Rats (n=6, one rat died between days 14-21) were repeatedly examined by PET before (day 0) and at 7, 14, 21 and 28 days after EAE to day 28 after EAE induction (P<0.05 with respect to control animals; Fig. 5h ). Hence, system xc − up-regulation was exhibited in the lumbar region, which might result in higher glutamate release and excitotoxic damage leading demyelination in this specific section of the spinal cord [6] .
Microglial regulation of xc − system expression with [
F] FSPG after EAE
System xc
− upregulation could be related to neuroinflammation, as previously described [6] . To determine whether microglial cells are responsible of system xc − activity upregulation in EAE, we selectively depleted these cells by intracerebroventricular injection of liposome-encapsulated clodronate after EAE induction [28] . Eight days post immunization (dpi), rats were treated either with clodronate (n=5) or vehicle (n=5). The rats were subjected to [
18 F]FSPG PET and immunofluorescence studies at days 6 (14 dpi, peak of EAE symptoms) and 7 (15 dpi) post-treatment (Fig. 6a) . Treated EAE rats with clodronate tended to increase the severity of neurological symptoms after EAE induction when compared to vehicle injected rats (Fig. 6b) . As expected, clodronate liposomes significantly reduced the number of Iba1 + microglial cells in hippocampal CA1 region and spinal cord (p<0.05 with respect to control EAE animals; Fig. 6c and d) . PET imaging with [ 18 F]FSPG at day 6 after treatment with clodronate showed a decrease of the binding uptake in relation to control EAE rats ( Fig. 7a and b) . Treatment with clodronate showed a nonsignificant PET signal decrease in cervical and thoracic sections of the spinal cord ( Fig. 7c and d) . In contrast, clodronate induced a significant reduction of [ 18 F]FSPG binding in relation to non-treated EAE rats in the lumbar section of the spinal cord (P<0.05, Fig. 7e ), suggesting the contribution of microglia on system xc − activity after EAE.
Discussion
The diagnosis and progression of MS might be supported by molecular imaging techniques when clinical symptoms have not been conclusive. Despite MRI having been used to detect the spatiotemporal distribution of sclerotic lesions [29] , this technique has shown several disadvantages, such as lack of specificity to detect the pathologic features of MS [30] . Likewise, PET has been applied to monitor specific biological aspects of MS, such as glucose metabolism [11, 12] , activated microglia/macrophages [14, 16, 17, 31] demyelination and remyelination [32] [33] [34] in rodent models of EAE. Nevertheless, clinical studies using PET have mainly been focused on the evaluation of changes in glucose metabolism and activated microglia/macrophages to evaluate the progression and therapy efficacy of MS [19, 25, 26] . Despite these findings, several pathological processes of interest for MS evolution remain unexplored by PET imaging. Hence, the identification of new upregulated transporters in reactive glial cells, such as cystine/glutamate antiporter xc − , which promotes the release of extracellular glutamate and excitotoxic damage to oligodendrocytes [6] , is of great interest to the in vivo imaging research of MS. Because of this, we have assessed in parallel the in vivo expression of the system xc − , TSPO and glucose metabolism in reactive glial cells using PET imaging procedures, in combination with MRI, immunohistochemistry and neurofunctional evaluation after EAE in rats longitudinally.
Neurological outcome and ventricle dilatation after EAE
The EAE in Lewis rats is characterized by a period of relapse and remission, thus reproducing hallmarks of the disease [16, 17] . Immunized rats showed clinical signs over day 10 after EAE induction, followed by a peak of symptoms at day 14 post immunization with complete hindlimb paralysis. The symptoms persisted for about 7 days and are followed by recovery to almost normal motor function skills. Hence, the clinical evolution of the disease was the rational for the design of the experimental set-up with both MRI and PET/CT in the present study (Fig. 1) . Multiple sclerosis is a chronic disease of the central nervous system characterized by inflammatory processes leading to brain edema and myelin damage [35] . In the present study, in vivo MRI-T 1 W showed a significant increase of the cerebral ventricle volume at day 14, followed by a swelling decrease from days 21 to 28 after EAE induction (Fig. 2) . The increase of ventricular enlargement runs in parallel with the peak of MS symptoms at day 14, followed by a progressive improvement at days 21-28 after immunization (Fig. 1) . Likewise, these results were consistent with ventricle volume changes in a relapsing-remitting model of EAE in mice [35] .
PET imaging of glucose metabolism with [
F]FDG
Previous in vivo PET studies in MS patients have been used as a marker of disease activity [25] , evidencing a decrease in glucose metabolism as a result of severe cognitive and mental dysfunction underlying MS [26, 36] . In contrast, [ 11 C]PK11195 (% ID/cc, mean±s.d.) was quantified in cerebrum (d), cerebellum (e), cervical (f), thoracic (g) and lumbar spinal cord (h). The upper right panels of each figure show the selected ROIs for the quantification defined in a representation of the rat central nervous system. Rats (n=6, one rat died between days 14-21) were repeatedly examined by PET before (day 0) and at 7, 14, 21 and 28 days after EAE. *P<0.05 compared with control inflammatory infiltrates in spinal cord of the EAE model in rats [12] and mice [11] [12] . In the present study, no significant differences in brain and spinal cord [ 18 F]FDG uptake were detected that stand in agreement with the findings showed by de Paula Faria and collaborators in a EAE rat model [31] (Fig. 3) . In fact, the lack of changes in [ 
In vivo PET imaging TSPO after EAE
TSPO receptors have become a potential target for the development of radiotracers to study neuroinflammation with PET due to its over-expression in response to the inflammatory environment [37] . [ 11 C]PK11195 is the first TSPO radioligand that could detect microglia/macrophages activation in MS patients [18, 19] and in rodents after EAE induction [18, 35] . Likewise, novel radiotracers have been recently used for imaging microglial activation in spinal cords of EAE [16, 17] . The present study showed an overall increase in TSPO expression in cerebellum and spinal cord at day 14 after EAE induction that runs in parallel with the neurological severity and ventricle enlargement reached at this time point (Fig. 4) . The fact that the highest [ 11 C]PK11195 binding uptake at control conditions was found in the thoracic region of the spinal cord might be attributed to spill-over effects from the lungs, which have a high expression of TSPO [38] . Besides, this is the reason for the lack of statistically PET binding differences in the thoracic spinal cord in comparison to cervical and lumbar sections. The highest [ 11 C]PK11195 binding uptake was observed in the lumbar spinal cord and progressively decreased from caudal to rostral sections of the CNS as follows: thoracic cord > cervical cord > cerebellum > cerebrum. These findings are consistent with Xie and collaborators who showed a similar ranking order for TSPO binding in spinal cords of EAE in Lewis rats [16] . Therefore, our results evidence an ascending inflammatory response that is most severe in the caudal regions of the spinal cord and decreases towards rostral regions of the CNS.
PET imaging of system xc − in CNS after EAE Previously, in vivo brain imaging of multiple sclerosis patients with magnetic resonance spectroscopy at 3 T (MRS) showed increased glutamate concentrations in acute lesions and normal-appearing white matter [39] . Despite these findings, the intercellular and subcellular compartmentalization of the neurotransmitter pool cannot be distinguished by MRS. -22] . This transport system is a sodium-independent transporter that mediates the cellular uptake of cystine in exchange for glutamate at a 1:1 ratio [21] . Likewise, this transporter is considered the main source of non-synaptic glutamate that contributes to enhance neuronal damage in ischemia and glioma-derived epileptic seizures [22, 40] . System xc − is not able to discriminate between cystine and glutamate for the inward transport [41] (1) to evaluate the spatiotemporal progression of the EAE in rats and (2) to discriminate spinal cord regions according to the damage degree following experimental MS. Likewise, these results also show the increase of the cystine/glutamate antiporter function in accordance with the complete hindlimb paralysis of EAE rats.
Ex vivo and in vivo evidences of microglial regulation of system xc − activity after EAE To confirm the relationship between the system xc − activity and neuroinflammation, microglia were selectively depleted with intracerebroventricular injection of liposomeencapsulated clodronate after EAE induction [32] . EAE rats treated with clodronate evidenced a significant decrease in Iba1 positive cells in the CA1 region of the hippocampus and in the spinal cord at day 15 after EAE induction (Fig. 6 ). Despite the microglial depletion, treated EAE rats with clodronate did not show a decrease on neurological symptoms at day 14 after immunization. In contrast, Popovich and collaborators observed hindlimb recovery after depletion of hematogenous macrophages by chronic intravenous clodronate treatment in EAE rats [42] . Hence, the absence of clinical recovery in our study might point towards hematogenous macrophages as a cause of the clinical severity in EAE [43] . Despite these differences, [
18 F]FSPG PET showed a significant binding decrease in the lumbar section of the spinal cord in those rats treated with clodronate in comparison to control EAE rats (Fig. 7) , evidencing the microglial source of cystine/glutamate antiporter activity after EAE in rats.
Summary and conclusions
We report here the PET imaging of [ 18 
